Editorial

Welcome to *Seminars in Thrombosis & Hemostasis* 2015: New (2013) Impact Factor and Most Highly Cited Articles

Emmanuel J. Favaloro, PhD, FFSc (RCPA)¹

¹ Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, New South Wales, Australia

Semin Thromb Hemost 2015;41:1–6.

Welcome to the start of another year with *Seminars in Thrombosis & Hemostasis* (STH). This is my 7th year as editor-in-chief, and my 10th year of editorial association with this journal, having originally served as a regional editor. First, I sincerely wish to thank all the contributors to STH over the past years, as well as the guest editors for these issues, and of course, the current and past senior and associate editors of the journal. There will be some changes to the editorial team over the forth coming 12 months, with an expansion of this team currently in plan. Also, Dr. Catherine Hayward has indicated she would like to step down from her role as senior editor. We sincerely thank her for her support in previous years and wish her continued success in her work. Last year represented a milestone for this journal, representing the 40th year of publication, a landmark that we celebrated with two special 40th anniversary celebratory issues.^{1,2}

I will also take this opportunity to thank the journal production team at Thieme Medical Publishers for their high production standards and for facilitating both the print and online issues of the journal. In particular, I would like to thank Subhankar De, the production editor for STH for managing the production process of STH issues and articles. I also wish to thank Kelly Coffey, a journals coordinator for Thieme Medical Publishers, as well as other key people at Thieme, some of who prefer to remain unnamed, for the additional support provided over the recent years.

This is also a fitting time to once again reflect on our journal's impact factor, which was 3.693 for 2013. This represents a drop from our 2012 impact factor of 4.216 (► **Fig. 1**). I am hopeful that this pattern reflects some stabilization of the STH impact factor at around 4 over the coming years. It might be of some interest to note that the impact factor for most thrombosis and hemostasis focused journals fell in 2013 compared with 2012 values (► **Fig. 2**). The

reason for this generalized fall in impact factor for thrombosis and hemostasis focused journals is unknown, although it could be at least in part due to continued development of additional publishing avenues from open access models. I have also previously highlighted,^{3,4} and would continue to assert, that the impact factor is not the only marker of journal "quality" that we should consider, given the existence of other biometric markers and the limitations of any individual marker (including the impact factor) as a "quality" indicator.

Nevertheless, for the potential interest of the readership and contributing authors, I have listed the highest 2013-cited, 2010/2011-published, contributions from this journal in ► **Table 1**.^{5–62} These contributions identify those publications most contributing to the 2013 impact factor, and each was cited five or more times in 2013. The top

Fig. 1 The impact factor for *Seminars in Thrombosis & Hemostasis*, from 2003 to 2013.

Address for correspondence Emmanuel J. Favaloro, PhD, FFSc (RCPA), Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW 2145, Australia (e-mail: emmanuel.favaloro@health.nsw.gov.au).

Issue Theme Thrombosis and Hemostasis Issues in Critically Ill Patients; Guest Editor, Marcel Levi, MD, PhD.

Copyright © 2015 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

DOI <http://dx.doi.org/10.1055/s-0035-1544217>. ISSN 0094-6176.

Table 1 Most highly (2013) cited (2010/2011-published) contributions from *Seminars in Thrombosis & Hemostasis*

1. Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. *Semin Thromb Hemost* 2012;38(6):565–575
2. Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. *Semin Thromb Hemost* 2012;38(2):178–184
3. Allman-Farinelli MA. Obesity and venous thrombosis: a review. *Semin Thromb Hemost* 2011;37(8):903–907
4. Ichinose A. Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. *Semin Thromb Hemost* 2011;37(4):382–388
5. Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. *Semin Thromb Hemost* 2012;38(4):375–384
6. De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. *Semin Thromb Hemost* 2011;37(3):226–236
7. Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. *Semin Thromb Hemost* 2012;38(2):200–212
8. Dentali F, Sironi AP, Ageno W, et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. *Semin Thromb Hemost* 2012;38(5):535–548
9. Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. *Semin Thromb Hemost* 2012;38(4):305–321
10. Ballmaier M, Germeshausen M. Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. *Semin Thromb Hemost* 2011;37(6):673–681
11. Adcock Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. *Semin Thromb Hemost* 2012;38(6):576–585
12. Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. *Semin Thromb Hemost* 2011;37(3):280–297
13. Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. *Semin Thromb Hemost* 2012;38(1):16–22
14. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? *Semin Thromb Hemost* 2012;38(4):322–327
15. Preissner KT, Reuning U. Vitronectin in vascular context: facets of a multitasking matricellular protein. *Semin Thromb Hemost* 2011;37(4):408–424
16. Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. *Semin Thromb Hemost* 2012;38(1):79–94
17. Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. *Semin Thromb Hemost* 2011;37(8):885–896
18. Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. *Semin Thromb Hemost* 2012;38(5):433–446
19. Nürden AT, Pillois X, Fiore M, Heilig R, Nürden P. Glanzmann thrombasthenia-like syndromes associated with Macrothrombocytopenias and mutations in the genes encoding the $\alpha\text{IIb}\beta 3$ integrin. *Semin Thromb Hemost* 2011;37(6):698–706
20. Plebani M, Favaloro EJ, Lippi G. Patient safety and quality in laboratory and hemostasis testing: a renewed loop? *Semin Thromb Hemost* 2012;38(6):553–558
21. Lippi G, Cervellin G. Degradation of troponin I in serum or plasma: mechanisms, and analytical and clinical implications. *Semin Thromb Hemost* 2012;38(2):222–229
22. Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. *Semin Thromb Hemost* 2011;37(5):440–455
23. Maas C, Oschatz C, Renné T. The plasma contact system 2.0. *Semin Thromb Hemost* 2011;37(4):375–381
24. Zeerleder S. C1-inhibitor: more than a serine protease inhibitor. *Semin Thromb Hemost* 2011;37(4):362–374
25. Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. *Semin Thromb Hemost* 2011;37(3):209–219
26. Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitasking participants in intercellular communication. *Semin Thromb Hemost* 2012;38(1):102–113
27. Di Fabio F, Lykoudis P, Gordon PH. Thromboembolism in inflammatory bowel disease: an insidious association requiring a high degree of vigilance. *Semin Thromb Hemost* 2011;37(3):220–225
28. Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. *Semin Thromb Hemost* 2012;38(4):385–389
29. Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II—Lupus anticoagulant. *Semin Thromb Hemost* 2012;38(4):404–411
30. Blavignac J, Bunimov N, Rivard GE, Hayward CP. Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment. *Semin Thromb Hemost* 2011;37(6):713–720
31. Hampshire DJ, Goodeve AC. The international society on thrombosis and haemostasis von Willebrand disease database: an update. *Semin Thromb Hemost* 2011;37(5):470–479
32. Hayward CP, Moffat KA, Liu Y. Laboratory investigations for bleeding disorders. *Semin Thromb Hemost* 2012;38(7):742–752
33. Lippi G, Plebani M, Favaloro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. *Semin Thromb Hemost* 2013;39(3):258–266
34. Lippi G, Favaloro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. *Semin Thromb Hemost* 2011;37(3):237–251
35. Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. *Semin Thromb Hemost* 2012;38(1):47–54
36. Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. *Semin Thromb Hemost* 2012;38(4):360–374

Table 1 (Continued)

37. Targher G, Pichiri I, Lippi G. Vitamin D, thrombosis, and hemostasis: more than skin deep. <i>Semin Thromb Hemost</i> 2012;38(1):114–124
38. Tufano A, Di Capua M, Coppola A, et al. The infectious burden in atherothrombosis. <i>Semin Thromb Hemost</i> 2012;38(5):515–523
39. Sørensen B, Larsen OH, Rea CJ, Tang M, Foley JH, Fenger-Eriksen C. Fibrinogen as a hemostatic agent. <i>Semin Thromb Hemost</i> 2012;38(3):268–273
40. Levi M, van der Poll T, Schultz M. Infection and inflammation as risk factors for thrombosis and atherosclerosis. <i>Semin Thromb Hemost</i> 2012;38(5):506–514
41. Kulkarni R, Soucie JM. Pediatric hemophilia: a review. <i>Semin Thromb Hemost</i> 2011;37(7):737–744
42. Tufano A, Coppola A, Cerbone AM, Ruosi C, Franchini M. Preventing postsurgical venous thromboembolism: pharmacological approaches. <i>Semin Thromb Hemost</i> 2011;37(3):252–266
43. van der Post JA, Lok CA, Boer K, Sturk A, Sargent IL, Nieuwland R. The functions of microparticles in pre-eclampsia. <i>Semin Thromb Hemost</i> 2011;37(2):146–152
44. Lockwood CJ, Huang SJ, Krikun G, et al. Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia. <i>Semin Thromb Hemost</i> 2011;37(2):158–164
45. Salmela B, Jouts-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. <i>Semin Thromb Hemost</i> 2012;38(1):23–30
46. Federici AB, Bucciarelli P, Castaman G, et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. <i>Semin Thromb Hemost</i> 2011;37(5):511–521
47. Franchini M, Lippi G, Favaloro EJ. Acquired inhibitors of coagulation factors: part II. <i>Semin Thromb Hemost</i> 2012;38(5):447–453
48. Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. <i>Semin Thromb Hemost</i> 2012;38(5):483–496
49. Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. <i>Semin Thromb Hemost</i> 2011;37(3):267–274
50. Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. <i>Semin Thromb Hemost</i> 2012;38(5):454–462
51. Favaloro EJ, Wheatland L, Jovanovich S, Roberts-Thomson P, Wong RC. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I—Anticardiolipin and anti- β 2-glycoprotein I antibodies. <i>Semin Thromb Hemost</i> 2012;38(4):390–403
52. de Groot PG, Urbanus RT. The future of antiphospholipid antibody testing. <i>Semin Thromb Hemost</i> 2012;38(4):412–420
53. Millikan PD, Balamohan SM, Raskind WH, Kacena MA. Inherited thrombocytopenia due to GATA-1 mutations. <i>Semin Thromb Hemost</i> 2011;37(6):682–689
54. Howard BM, Daley AT, Cohen MJ. Prohemostatic interventions in trauma: resuscitation-associated coagulopathy, acute traumatic coagulopathy, hemostatic resuscitation, and other hemostatic interventions. <i>Semin Thromb Hemost</i> 2012;38(3):250–258
55. Montagnana M, Meschi T, Borghi L, Lippi G. Thrombosis and occlusion of vascular access in hemodialyzed patients. <i>Semin Thromb Hemost</i> 2011;37(8):946–954
56. Toriello HV. Thrombocytopenia-absent radius syndrome. <i>Semin Thromb Hemost</i> 2011;37(6):707–712
57. Di Paola J, Johnson J. Thrombocytopenias due to gray platelet syndrome or THC2 mutations. <i>Semin Thromb Hemost</i> 2011;37(6):690–697
58. Lippi G, Franchini M, Cervellin G. Diagnosis and management of ischemic heart disease. <i>Semin Thromb Hemost</i> 2013;39(2):202–213

Fig. 2 The relative change in impact factor (IF) from 2012 to 2013 for eight thrombosis and hemostasis-focused journals. Data shown as IF change from 2012 to 2013 in absolute terms (left axis; gray bars) and as a percentage change (right axis; hatched bars). The data for *Seminars in Thrombosis & Hemostasis* identified as STH.

Table 2 Current planned topics for future issues of Seminars in Thrombosis and Hemostasis

- Thrombosis and hemostasis issues in critically ill patients
- Anticoagulant therapy: present and future
- Current issues in hemophilia: recognizing clinical heterogeneity, replacement therapy, and outcome assessment
- Tissue factor in arterial and venous thrombosis. From pathophysiology to clinical implications
- Hemostatic dysfunction in liver diseases
- Hot topics VII (continuing series)
- Quality in thrombosis and hemostasis (continuing series)

20-listed articles^{5–24} were each actually cited 10 or more times in 2013. For those interested, the current listing can be compared with those of the most recently published top downloaded article listings from STH, the basis of the Eberhard Mammen “Most Popular” awards.^{63,64} Accordingly, I thank all the contributors, guest editors, and the editorial team for bringing us the content that makes STH.

Finally, a short note to confirm that we will continue to develop plans for the future content of this journal, and we are confident that we will be able to continue to bring you, the reader, the high-quality journal that you have come to expect. Currently confirmed topics for issues that we plan to publish over the next 12 or so months are listed in ▶Table 2. At the same time, we recognize the need to retain some flexibility in our plans, and to potentially add additional material of current interest and controversy as the need arises.

We look forward to another interesting year of reading in 2015!

References

- Favaloro EJ. A short history of thrombosis and hemostasis: part I (40th year celebratory issue). *Semin Thromb Hemost* 2014;40(5): 521–525
- Favaloro EJ. A short history of thrombosis and hemostasis: part II (40th year celebratory issue). *Semin Thromb Hemost* 2014;40(8): 826–830
- Favaloro EJ. The Journal Impact Factor: don't expect its demise any time soon. *Clin Chem Lab Med* 2009;47(11):1319–1324
- Favaloro EJ. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. *Semin Thromb Hemost* 2008;34(1):7–25
- Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. *Semin Thromb Hemost* 2012;38(6):565–575
- Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. *Semin Thromb Hemost* 2012; 38(2):178–184
- Allman-Farinelli MA. Obesity and venous thrombosis: a review. *Semin Thromb Hemost* 2011;37(8):903–907
- Ichinose A. Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. *Semin Thromb Hemost* 2011;37(4):382–388
- Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. *Semin Thromb Hemost* 2012;38(4): 375–384
- De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. *Semin Thromb Hemost* 2011;37(3):226–236
- Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. *Semin Thromb Hemost* 2012; 38(2):200–212
- Dentali F, Sironi AP, Ageno W, et al. Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature. *Semin Thromb Hemost* 2012;38(5):535–548
- Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. *Semin Thromb Hemost* 2012;38(4):305–321
- Ballmaier M, Germeshausen M. Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. *Semin Thromb Hemost* 2011;37(6):673–681
- Adcock Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. *Semin Thromb Hemost* 2012;38(6):576–585
- Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. *Semin Thromb Hemost* 2011;37(3):280–297
- Harenberg J, Giese C, Marx S, Krämer R. Determination of dabigatran in human plasma samples. *Semin Thromb Hemost* 2012; 38(1):16–22
- Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? *Semin Thromb Hemost* 2012;38(4):322–327
- Preissner KT, Reuning U. Vitronectin in vascular context: facets of a multitasking matricellular protein. *Semin Thromb Hemost* 2011; 37(4):408–424
- Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. *Semin Thromb Hemost* 2012;38(1):79–94
- Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. *Semin Thromb Hemost* 2011;37(8):885–896
- Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I—acquired hemophilia A. *Semin Thromb Hemost* 2012;38(5): 433–446
- Nurden AT, Pillois X, Fiore M, Heilig R, Nurden P. Glanzmann thrombasthenia-like syndromes associated with Macrothrombocytopenias and mutations in the genes encoding the $\alpha IIb\beta 3$ integrin. *Semin Thromb Hemost* 2011;37(6):698–706
- Plebani M, Favaloro EJ, Lippi G. Patient safety and quality in laboratory and hemostasis testing: a renewed loop? *Semin Thromb Hemost* 2012;38(6):553–558
- Lippi G, Cervellin G. Degradation of troponin I in serum or plasma: mechanisms, and analytical and clinical implications. *Semin Thromb Hemost* 2012;38(2):222–229
- Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. *Semin Thromb Hemost* 2011;37(5):440–455
- Maas C, Oschatz C, Renné T. The plasma contact system 2.0. *Semin Thromb Hemost* 2011;37(4):375–381
- Zeerleder S. C1-inhibitor: more than a serine protease inhibitor. *Semin Thromb Hemost* 2011;37(4):362–374
- Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. *Semin Thromb Hemost* 2011;37(3): 209–219
- Aatonen M, Grönholm M, Siljander PR. Platelet-derived microvesicles: multitasking participants in intercellular communication. *Semin Thromb Hemost* 2012;38(1):102–113
- Di Fabio F, Lykoudis P, Gordon PH. Thromboembolism in inflammatory bowel disease: an insidious association requiring a high degree of vigilance. *Semin Thromb Hemost* 2011;37(3):220–225
- Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. *Semin Thromb Hemost* 2012;38(4): 385–389
- Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II—Lupus anticoagulant. *Semin Thromb Hemost* 2012; 38(4):404–411
- Blavignac J, Bunimov N, Rivard GE, Hayward CP. Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment. *Semin Thromb Hemost* 2011;37(6):713–720
- Hampshire DJ, Goodeve AC. The international society on thrombosis and haemostasis von Willebrand disease database: an update. *Semin Thromb Hemost* 2011;37(5):470–479
- Hayward CP, Moffat KA, Liu Y. Laboratory investigations for bleeding disorders. *Semin Thromb Hemost* 2012;38(7):742–752

- 37 Lippi G, Plebani M, Favalaro EJ. Interference in coagulation testing: focus on spurious hemolysis, icterus, and lipemia. *Semin Thromb Hemost* 2013;39(3):258–266
- 38 Lippi G, Favalaro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. *Semin Thromb Hemost* 2011;37(3):237–251
- 39 Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. *Semin Thromb Hemost* 2012;38(1):47–54
- 40 Willis R, Harris EN, Pierangeli SS. Current international initiatives in antiphospholipid antibody testing. *Semin Thromb Hemost* 2012;38(4):360–374
- 41 Targher G, Pichiri I, Lippi G. Vitamin D, thrombosis, and hemostasis: more than skin deep. *Semin Thromb Hemost* 2012;38(1):114–124
- 42 Tufano A, Di Capua M, Coppola A, et al. The infectious burden in atherothrombosis. *Semin Thromb Hemost* 2012;38(5):515–523
- 43 Sørensen B, Larsen OH, Rea CJ, Tang M, Foley JH, Fenger-Eriksen C. Fibrinogen as a hemostatic agent. *Semin Thromb Hemost* 2012;38(3):268–273
- 44 Levi M, van der Poll T, Schultz M. Infection and inflammation as risk factors for thrombosis and atherosclerosis. *Semin Thromb Hemost* 2012;38(5):506–514
- 45 Kulkarni R, Soucie JM. Pediatric hemophilia: a review. *Semin Thromb Hemost* 2011;37(7):737–744
- 46 Tufano A, Coppola A, Cerbone AM, Ruosi C, Franchini M. Preventing postsurgical venous thromboembolism: pharmacological approaches. *Semin Thromb Hemost* 2011;37(3):252–266
- 47 van der Post JA, Lok CA, Boer K, Sturk A, Sargent IL, Nieuwland R. The functions of microparticles in pre-eclampsia. *Semin Thromb Hemost* 2011;37(2):146–152
- 48 Lockwood CJ, Huang SJ, Krikun G, et al. Decidual hemostasis, inflammation, and angiogenesis in pre-eclampsia. *Semin Thromb Hemost* 2011;37(2):158–164
- 49 Salmela B, Jouts-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. *Semin Thromb Hemost* 2012;38(1):23–30
- 50 Federici AB, Bucciarelli P, Castaman G, et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. *Semin Thromb Hemost* 2011;37(5):511–521
- 51 Franchini M, Lippi G, Favalaro EJ. Acquired inhibitors of coagulation factors: part II. *Semin Thromb Hemost* 2012;38(5):447–453
- 52 Prechel M, Walenga JM. Heparin-induced thrombocytopenia: an update. *Semin Thromb Hemost* 2012;38(5):483–496
- 53 Tufano A, Guida A, Di Minno MN, Prisco D, Cerbone AM, Di Minno G. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. *Semin Thromb Hemost* 2011;37(3):267–274
- 54 Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. *Semin Thromb Hemost* 2012;38(5):454–462
- 55 Favalaro EJ, Wheatland L, Jovanovich S, Roberts-Thomson P, Wong RC. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I—Anticardiolipin and anti- β 2-glycoprotein I antibodies. *Semin Thromb Hemost* 2012;38(4):390–403
- 56 de Groot PG, Urbanus RT. The future of antiphospholipid antibody testing. *Semin Thromb Hemost* 2012;38(4):412–420
- 57 Millikan PD, Balamohan SM, Raskind WH, Kacena MA. Inherited thrombocytopenia due to GATA-1 mutations. *Semin Thromb Hemost* 2011;37(6):682–689
- 58 Howard BM, Daley AT, Cohen MJ. Prohemostatic interventions in trauma: resuscitation-associated coagulopathy, acute traumatic coagulopathy, hemostatic resuscitation, and other hemostatic interventions. *Semin Thromb Hemost* 2012;38(3):250–258
- 59 Montagnana M, Meschi T, Borghi L, Lippi G. Thrombosis and occlusion of vascular access in hemodialyzed patients. *Semin Thromb Hemost* 2011;37(8):946–954
- 60 Toriello HV. Thrombocytopenia-absent radius syndrome. *Semin Thromb Hemost* 2011;37(6):707–712
- 61 Di Paola J, Johnson J. Thrombocytopenias due to gray platelet syndrome or *THC2* mutations. *Semin Thromb Hemost* 2011;37(6):690–697
- 62 Lippi G, Franchini M, Cervellin G. Diagnosis and management of ischemic heart disease. *Semin Thromb Hemost* 2013;39(2):202–213
- 63 Favalaro EJ. 2013 Eberhard F. Mammen award announcements. *Semin Thromb Hemost* 2013;39(6):567–574
- 64 Favalaro EJ. 2014 Eberhard F. Mammen Award announcements: Part I—Most popular articles. *Semin Thromb Hemost* 2014;40(4):407–412